Multiple Myeloma | Clinical

May 07, 2021

In an interview with Targeted Oncology, Bishop, discussed how CAR T cells have reshaped the treatment landscape, the future of their use, and their potential in solid tumors.

May 07, 2021

During a Targeted Oncology Case-Based Roundtable event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.

May 06, 2021

In patients with multiple myeloma, the combination of motixafortide and granulocyte colony-stimulating factor achieved a 4.9-fold increase in hematopoietic stem-cell mobilization, and prepared most patients for autologous stem cell transplant, meeting both the primary and main secondary endpoints of the GENESIS Study.

April 30, 2021

Nicolaus Kröger, MD, discusses the advantages of autologous stem cell transplant and allogeneic stem cell transplant compared with autologous tandem transplant in patients with multiple myeloma.

April 30, 2021

Melissa Alsina, MD, reviewed the treatment options for transplant-eligible multiple myeloma based on the case of a 52-year-old male patient.

April 26, 2021

Multiple myeloma expert, Dr Clifton Mo, shares his insights on future directions for the treatment of multiple myeloma.

April 26, 2021

An expert hematologist-oncologist provides his perspective on the importance of managing toxicities in patients with relapsed/refractory multiple myeloma.

April 26, 2021

Clifton C. Mo, MD, reviews the ongoing multicenter phase 1 STOMP trial in relapsed/refractory multiple myeloma.

April 26, 2021

An expert hematologist-oncologist reviews the randomized, phase 3 BOSTON trial of a selinexor-based triplet regimen for the treatment of multiple myeloma.

April 26, 2021

Dr Clifton Mo describes second-line treatment options for the management of multiple myeloma, and treatment approaches for IMiD- and anti-CD38–refractory MM.